|1.||Thibaud, D: 4 articles (07/2010 - 06/2003)|
|2.||Thibaud, Dominique: 3 articles (01/2011 - 03/2007)|
|3.||Bertaim, Thierry: 2 articles (01/2011 - 01/2011)|
|4.||Pelletier, Jean-Pierre: 2 articles (01/2011 - 01/2011)|
|5.||Lussier, Bertrand: 2 articles (01/2011 - 01/2011)|
|6.||Troncy, Eric: 2 articles (01/2011 - 01/2011)|
|7.||Martel-Pelletier, Johanne: 2 articles (01/2011 - 01/2011)|
|8.||Caron, Judith: 2 articles (01/2011 - 01/2011)|
|9.||Moreau, Maxim: 2 articles (01/2011 - 01/2011)|
|10.||Garnero, P: 2 articles (04/2008 - 09/2007)|
01/01/1999 - "Following treatment with the bone resorption inhibitor tiludronate, the morphometric parameters were significantly improved. "
01/01/1995 - "Tiludronate appears effective in reducing bone resorption without impairing bone formation in a manner that preserved bone mass and bone cell coupling."
11/01/1995 - "Bone tolerance studies indicate that tiludronate is a safe compound with an appreciable therapeutic margin since it can effectively inhibit bone resorption without reducing bone mineralization and strength. "
04/01/2008 - "Comparative pharmacokinetics of two intravenous administration regimens of tiludronate in healthy adult horses and effects on the bone resorption marker CTX-1."
11/01/1995 - "The available preclinical data indicate that tiludronate should be an efficacious bisphosphonate in the management of clinical conditions characterized by excessive bone resorption."
|2.||Osteitis Deformans (Paget's Disease of Bone)
08/01/1997 - "A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone."
11/01/1995 - "The methodology of clinical trials of oral tiludronate in Paget's disease of bone."
11/01/1995 - "A double-blind, randomized, placebo-controlled study was performed to evaluate the effect of oral tiludronate therapy in 139 patients with active Paget's disease of bone. "
01/01/2002 - "Results for these women were compared with those of 29 patients with Paget's disease of bone treated with tiludronate (400 mg/day) for 3 months, and with those of a group of 21 healthy premenopausal women (control group I). "
09/01/1997 - "Comparison of the efficacy and bioequivalence of two oral formulations of tiludronate in the treatment of Paget's disease of bone."
03/01/2007 - "Tiludronate had efficacy in the treatment of horses with signs of pain induced by osteoarticular lesions of the thoracolumbar vertebral column, causing a significant improvement in dorsal flexibility. "
03/01/2007 - "To evaluate the efficacy of tiludronate for the treatment of horses with signs of pain associated with lesions of the thoracolumbar vertebral column. "
03/01/2007 - "Efficacy of tiludronate in the treatment of horses with signs of pain associated with osteoarthritic lesions of the thoracolumbar vertebral column."
11/01/1999 - "Several open uncontrolled, open randomised, and double-blind, placebo-controlled studies carried out in patients with active Paget's disease have demonstrated that tiludronate reduces bone pain and produces an intense and sustained biochemical response. "
03/01/2007 - "Tiludronate may offer a treatment option for the management of horses with intervertebral lesions and the associated pain."
03/01/1997 - "A group of 366 healthy, white postmenopausal women, aged 50-81 years, mean age 66 years, were selected from the screened population of Scandinavians who were part of a multicenter study of the efficacy of tiludronate, a new bisphosphonate, in established postmenopausal osteoporosis. "
01/01/2001 - "The objective of the study was to determine the efficacy and safety of tiludronate in the treatment of postmenopausal osteoporosis. "
01/01/2001 - "Thus, tiludronate, administered at these doses in a cyclic intermittent regimen, cannot be considered an appropriate treatment of postmenopausal osteoporosis, notwithstanding a high safety profile."
01/01/1996 - "Tiludronate prevents trabecular postmenopausal bone loss. "
12/01/1991 - "Tiludronate is a new bisphosphonate whose efficacy has already been reported for the prevention of postmenopausal bone loss. "
|5.||Metabolic Bone Diseases (Osteopenia)
10/01/1997 - "Bisphosphonate tiludronate increases bone strength by improving mass and structure in established osteopenia after ovariectomy in rats."
01/01/1995 - "Tiludronate was shown effective in reducing bone resorption in several metabolic bone diseases without inducing mineralization defects. "
09/01/2007 - "Tiludronate was found to significantly reduce bone resorption during immobilization, as well as to prevent long-term osteopenia in the immobilized limb. "
|1.||Etidronic Acid (HEDP)
|2.||tiludronic acid (tiludronate)
|3.||Alendronate (Alendronate Sodium)
|5.||risedronic acid (risedronate)
|6.||Biological Markers (Surrogate Marker)
|9.||Clodronic Acid (Clodronate)
|10.||ibandronic acid (Boniva)